Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06282705
Other study ID # 306347
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 6, 2023
Est. completion date December 13, 2023

Study information

Verified date February 2024
Source Nottingham Trent University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study aims to assess if a 16-week drop jump intervention from different heights shows different bone adaptations. Participants will complete four visits over a period of 16 weeks. An initial consultation will be conducted to ensure participants meet the inclusion criteria following participant recruitment. Estimated load being applied to the bone, will be assessed using non-invasive biomechanical procedures (Inertial Measurement Units, motion analysis, force plates) during drop jumps. Participants will be assigned a drop jump height of 0 cm, 30 cm or 60 cm based on a significant difference in external load at these heights or assigned to a control group where no jumps will be performed. Groups will be matched for body mass to ensure that jump height produces the load. The participants will be asked to perform 40 jumps (20 each side), 4 times per week ensuring jumping bouts are separated by 24 hours. Bone characteristics will be assessed via whole body dual-energy X-ray absorptiometry (DXA) scans and bilateral peripheral Quantitative Computed Tomography (pQCT) scans. Lab based jumping will take place on week 0, week 6, week 12, and week 16 to understand the loading applied during the different jump height groups. pQCT scans will take place on week 0, week 12, week 16 and DXA scans will take place week 0 and week 16. The reasoning of week 12 for pQCT being it may show a significant timepoint for bone formation during the remodelling cycle. During visits participants will complete a health screen, the Bone specific Physical Activity Questionnaire (BPAQ), a food frequency questionnaire and Pittsburgh sleep quality questionnaire alongside consent as tools to monitor any changes to participant lifestyle across the study. Differences in bone characteristics, lab measures and jump heights will be analysed between and within participants. The present study aims to use varied drop jump heights to identify an osteogenic dose response effect. Drop jumps have been previously used to expose osteogenic effects in research due to the load produced at impact. Is it possible to identify an optimum height for bone response during impact? If so do we then find anything above this height actually has negative or no effect on a group of individuals?


Description:

There are few studies that attempt to identify optimal exercises for bone health with specific loading variables being quantified. The identification of an osteogenic threshold during single or multiple activity bouts would allow us to understand the optimal volume/magnitude of exercise/loading that causes an osteogenic response. Understanding the optimal exercise characteristics for osteogenesis will subsequently allow specific bone enhancing exercise to be prescribed. Currently, ambiguity exists as in the guidance for optimising bone health through exercise, for example, a recently published position statement on increasing peak bone mass in adolescents recommends that 5-6 months of vigorous physical activity should be performed but does not quantify the specific speed or intensity of activity required. pQCT and DXA will be used to measure bone characteristics. Both methods are a common way of obtaining data detailing bone architecture and geometry within established research establishments including universities and National Health Service (NHS) trusts. Through pQCT, bone geometry, both cortical and trabecular bone can be measured and as a result, bone quality can be assessed. Bone measurement via pQCT is widely used in research and is a non-invasive method of imaging bone to provide estimates of bone strength in the peripheral skeleton to differentiate cortical from trabecular bone and assess bone geometry and density. DXA is the gold standard method of measuring bone mineral density and is commonly used to assess osteoporosis risk. In addition, body composition (which will be derived from the DXA) may be associated with bone characteristics due to body mass and composition relating to bone loading and muscle acting on bone to produce bone strain.


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date December 13, 2023
Est. primary completion date December 13, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 25 Years
Eligibility Inclusion Criteria: - 18 to 25 years old - Have a low physical activity status defined as partaking in physical training activities no more than 2x per week. - No current regular participation (more than once per week) in exercise programmes known to influence bone inc. gymnastics, dance, court sports, ball sports or racquet sports. - Be able to travel to the laboratory using a vehicle or public transport - Have the ability to comprehend and understand communication and instruction in English in order to consent and safely participate in study. - Have no current unresolved cardiovascular complaints to avoid any cardiovascular complications when performing activities of daily living. Exclusion Criteria: - Prescribed medication that influences bone metabolism such as corticosteroids, anticancer drugs, and diabetes related Drugs - Joint replacement or prostheses - Currently or recently injured - Medical conditions adversely affected by exposure to ionising radiation. - History of high levels of ionising radiation exposure (e.g., medical treatment). - Breastfeeding women, pregnant women and women trying to become pregnant - Females who are on any form of contraception that may influence changes in bone - Females who have current or previous history of an endocrine disorder

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Diagonal Drop Jumps 0cm
Participants will complete 4 unsupervised home drop jump sessions per week ( minimum 24 hours between each session) for the duration of the study (e.g., Mon, Wed, Fri, Sun) from a height of 0 cm (floor). They will perform 20 diagonal drop jumps on each side (20 x dropping left and 20 x dropping right) with 30 seconds between each jump. The routine will be demonstrated in full on the first laboratory session. The intervention will last 16 weeks.
Diagonal Drop Jumps 40cm
Participants will complete 4 unsupervised home drop jump sessions per week ( minimum 24 hours between each session) for the duration of the study (e.g., Mon, Wed, Fri, Sun) from a height of 40 cm (plyo box). They will perform 20 diagonal drop jumps on each side (20 x dropping left and 20 x dropping right) with 30 seconds between each jump. The routine will be demonstrated in full on the first laboratory session. The intervention will last 16 weeks.
Diagonal Drop Jumps 60cm
Participants will complete 4 unsupervised home drop jump sessions per week ( minimum 24 hours between each session) for the duration of the study (e.g., Mon, Wed, Fri, Sun) from a height of 60 cm (plyo box). They will perform 20 diagonal drop jumps on each side (20 x dropping left and 20 x dropping right) with 30 seconds between each jump. The routine will be demonstrated in full on the first laboratory session. The intervention will last 16 weeks.

Locations

Country Name City State
United Kingdom Nottingham Trent University Nottingham Nottinghamshire

Sponsors (1)

Lead Sponsor Collaborator
Nottingham Trent University

Country where clinical trial is conducted

United Kingdom, 

References & Publications (2)

Kenkre JS, Bassett J. The bone remodelling cycle. Ann Clin Biochem. 2018 May;55(3):308-327. doi: 10.1177/0004563218759371. Epub 2018 Mar 4. — View Citation

Min SK, Oh T, Kim SH, Cho J, Chung HY, Park DH, Kim CS. Position Statement: Exercise Guidelines to Increase Peak Bone Mass in Adolescents. J Bone Metab. 2019 Nov;26(4):225-239. doi: 10.11005/jbm.2019.26.4.225. Epub 2019 Nov 30. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary BMD as assessed by whole body dual-energy X-ray absorptiometry (DXA). Bone mineral density (BMD) From baseline (week 0) to end of intervention (week 16)
Primary BMC as assessed by whole body dual-energy X-ray absorptiometry (DXA). Bone mineral content (BMC) From baseline (week 0) to end of intervention (week 16)
Primary Total bone area as assessed by whole body dual-energy X-ray absorptiometry (DXA). Total bone area From baseline (week 0) to end of intervention (week 16)
Primary Trabecular density as assessed by peripheral quantitative tomography (pQCT) of tibia. Trabecular density measured at the 4% site of the tibia length. From baseline (week 0) to mid intervention (week 12) and end of intervention (week 16)
Primary Cortical thickness as assessed by peripheral quantitative tomography (pQCT) of tibia. Cortical thickness measured at the 14% and 38% site of the tibial length. From baseline (week 0) to mid intervention (week 12) and end of intervention (week 16)
Primary Periosteal circumference as assessed by peripheral quantitative tomography (pQCT) of tibia. Periosteal circumference measured at the 14% and 38% site of the tibial length. From baseline (week 0) to mid intervention (week 12) and end of intervention (week 16)
Primary Axial bone strength (SSIX) as assessed by peripheral quantitative tomography (pQCT) of tibia. SSIX measured at the 14% and 38% site of the tibial length. From baseline (week 0) to mid intervention (week 12) and end of intervention (week 16)
Primary Axial bone strength (SSIY) as assessed by peripheral quantitative tomography (pQCT) of tibia. SSIY measured at the 14% and 38% site of the tibial length. From baseline (week 0) to mid intervention (week 12) and end of intervention (week 16)
Primary Polar bone strength (SSIPOL) as assessed by peripheral quantitative tomography (pQCT) of tibia. SSIPOL measured at the 14% and 38% site of the tibial length. From baseline (week 0) to mid intervention (week 12) and end of intervention (week 16)
Primary Cortical density as assessed by peripheral quantitative tomography (pQCT) of tibia. Cortical density measured at the 14%, 38% and 66% site of the tibial length. From baseline (week 0) to mid intervention (week 12) and end of intervention (week 16)
Secondary Peak impact load as assessed by force plates. Peak impact load derived from ground reaction force (GRF) From baseline (week 0) to mid intervention (week 6, week 12) and end of intervention (week 16)
Secondary Impulse as assessed by force plates. Impulse derived from ground reaction force (GRF) From baseline (week 0) to mid intervention (week 6, week 12) and end of intervention (week 16)
Secondary Load rate as assessed by force plates. Load rate derived from ground reaction force (GRF) From baseline (week 0) to mid intervention (week 6, week 12) and end of intervention (week 16)
Secondary Jump height as assessed by force plates. Jump height derived from ground reaction force (GRF) From baseline (week 0) to mid intervention (week 6, week 12) and end of intervention (week 16)
Secondary Centre of Mass (CoM) velocity as assessed by force plates. CoM velocity derived from ground reaction force (GRF) From baseline (week 0) to mid intervention (week 6, week 12) and end of intervention (week 16)
Secondary Peak acceleration as assessed by Inertial measurement units (IMU). Peak accelerations calculated from tibial mounted IMUs. From baseline (week 0) to mid intervention (week 6, week 12) and end of intervention (week 16)
Secondary Stiffness as assessed by motion capture. Knee and ankle Stiffness derived from motion capture. From baseline (week 0) to mid intervention (week 6, week 12) and end of intervention (week 16)
Secondary Moments as assessed by motion capture. Knee and ankle moments derived from motion capture. From baseline (week 0) to mid intervention (week 6, week 12) and end of intervention (week 16)
See also
  Status Clinical Trial Phase
Completed NCT05445440 - A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine Phase 1
Completed NCT03712540 - An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants Phase 1
Completed NCT03649165 - A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants Phase 1
Completed NCT05956002 - A Study to Evaluate the Study Medication (Etrasimod) When Mixed With Food in Healthy Participants Phase 1
Completed NCT05539976 - A Taste Assessment of Iberdomide and Mezigdomide in Healthy Participants
Withdrawn NCT04558216 - Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy Participants Phase 1
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT06097390 - A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III Phase 1
Completed NCT05546151 - A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent Phase 1
Completed NCT05056246 - Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants Phase 1
Completed NCT04390776 - Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules. Phase 1
Completed NCT05074459 - A Study in Healthy Adults Investigating Eptinezumab Produced by 2 Different Manufacturing Cell Lines Phase 1
Enrolling by invitation NCT06089109 - Creating VIP Corps to Reduce Maternal Deaths N/A
Completed NCT05996250 - Tolerance of an Immersive Virtual Reality Task Evaluating the Spatial Memory of Elderly Subjects N/A
Completed NCT03278080 - Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #1 N/A
Completed NCT05064800 - PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants Phase 1
Completed NCT04471298 - A Study of Qishenyiqi Dripping Pills in Healthy Participants Phase 1
Completed NCT04914936 - A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196 Phase 1
Completed NCT02882386 - Amino Acid Kinetics in Blood After Consuming Different Milk Protein Supplements N/A
Completed NCT01681186 - A Study of LY2940680 in Healthy Participants Phase 1